Search
Oregon Paid Clinical Trials
A listing of 1217 clinical trials in Oregon actively recruiting volunteers for paid trials and research studies in various therapeutic areas.
1081 - 1092 of 1217
Match to Clinical Trials
Access to cutting-edge treatments
Latest clinical trials
Find trials in your area
Search by Name
Filter by Condition
Filter by Location
Filter by Age
Filter by Type
Gender
Type of Study
Clinical Trial Phase
Oregon is currently home to 1217 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Portland, Eugene, Medford and Clackamas. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Featured Trial
Paid Clinical Studies Nationwide
Recruiting
Nationwide clinical trials offered in your area. Some trials offering up to several thousand dollars in compensation for participation.
Featured Trial
Chronic Cough Research Study
Recruiting
Are you tired of living with chronic cough? Our research study is now looking to enroll people from all backgrounds to help research potential new treatment options for chronic cough.
You are under no obligation to take part and health insurance is not required. Find out more today! We’d love to hear from you!
You are under no obligation to take part and health insurance is not required. Find out more today! We’d love to hear from you!
Conditions:
Chronic Cough
Refractory or Unexplained Chronic Cough
Cough
Asthma
Sinusitis
Featured Trial
Dilated Cardiomyopathy (DCM) Research Study
Recruiting
If you are identified as eligible for investigational genetic testing, you will be sent a saliva collection kit to your home. Once you have completed and returned your kit to Sano Genetics, your sample will be tested for a specific genetic pathway called BAG3.
Investigational genetic testing can help you better understand your body and its needs, as well as how DCM may be passed down in your family. Those who are identified as having a variant in the BAG3 gene will be referred to an upcoming clinical trial.
Investigational genetic testing can help you better understand your body and its needs, as well as how DCM may be passed down in your family. Those who are identified as having a variant in the BAG3 gene will be referred to an upcoming clinical trial.
Conditions:
Dilated Cardiomyopathy (DCM)
Cardiovascular Diseases
Cardiomyopathy
Cardiovascular Disease
Heart Failure
Featured Trial
Parkinson's Disease: Genetic Testing and Clinical Trial
Recruiting
Sano is launching a new study to understand the genetics of Parkinson’s and give researchers the data they need to better understand this condition. By participating, you will support cutting-edge research and help pave the way for future breakthroughs. You may be referred to participate in a clinical trial.
By participating in this study, you can:
- Receive a first-of-its-kind, Parkinson's genetic test at home, cost free
- Understand your eligibility for an investigational clinical trial in Parkinson's disease
- Receive notifications for future research opportunities
- Access expert, condition-specific educational materials tailored to Parkinson's disease
By participating in this study, you can:
- Receive a first-of-its-kind, Parkinson's genetic test at home, cost free
- Understand your eligibility for an investigational clinical trial in Parkinson's disease
- Receive notifications for future research opportunities
- Access expert, condition-specific educational materials tailored to Parkinson's disease
Conditions:
Parkinson's Disease
Parkinson Disease
Parkinson's Disease (PD)
Idiopathic Parkinson's Disease
Parkinsonian Disorders
Featured Offer
Lose Weight with GLP-1 Medications
Recruiting
Policy Lab has partnered with OnlineSemaglutide.org to offer trusted access to semaglutide and other GLP-1 medications, including generic alternatives to Ozempic® and Wegovy®.
GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $100 off your first program with code policy-lab-100.
GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $100 off your first program with code policy-lab-100.
Conditions:
Overweight
Overweight and Obesity
Obesity
Weight Loss
Morbid Obesity
Crizotinib in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Removed by Surgery and ALK Fusion Mutations (An ALCHEMIST Treatment Trial)
Recruiting
This randomized phase III trial studies how well crizotinib works in treating patients with stage IB-IIIA non-small cell lung cancer that has been removed by surgery and has a mutation in a protein called anaplastic lymphoma kinase (ALK). Mutations, or changes, in ALK can make it very active and important for tumor cell growth and progression. Crizotinib may stop the growth of tumor cells by blocking the ALK protein from working. Crizotinib may be an effective treatment for patients with non-sma... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/29/2024
Locations: Saint Alphonsus Medical Center-Baker City, Baker City, Oregon
Conditions: ALK Gene Rearrangement, ALK Gene Translocation, ALK Positive, Stage IB Non-Small Cell Lung Carcinoma AJCC v7, Stage II Non-Small Cell Lung Cancer AJCC v7, Stage IIA Non-Small Cell Lung Carcinoma AJCC v7, Stage IIB Non-Small Cell Lung Carcinoma AJCC v7, Stage IIIA Non-Small Cell Lung Cancer AJCC v7
Metformin Use in Patients Undergoing Total Joint Replacement Surgery
Recruiting
The goal of this pilot, randomized, single-blind, placebo-controlled trial is to evaluate the feasibility of and provide preliminary information for a multi-center randomized controlled trial that will assess the effects of metformin on blood sugar control in patients after total hip or total knee replacement surgery.
The primary objective of this study is to assess the feasibility of conducting a large, randomized trial with regards to timely recruitment, study drug administration, protocol ad... Read More
Gender:
ALL
Ages:
Between 18 years and 99 years
Trial Updated:
06/27/2024
Locations: Oregon Health & Science University, Portland, Oregon
Conditions: Hyperglycemia
Support Via Technology: Living and Learning With Advancing Dementia-REVISED
Recruiting
STELLA-R is a multicomponent, self-directed, online intervention designed to facilitate effective management of behavioral and psychological symptoms that are common in many types of dementia. The curriculum instructs care partners to use the ABC approach, a cognitive behavioral technique that teaches care partners to describe a Behavior, then consider the Activators and Consequences of a care recipient behavior. The goal of this intervention is to reduce care partner burden and decrease reactiv... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/26/2024
Locations: Oregon Health & Science University, Layton Aging and Alzheimer's Disease Research Center, Portland, Oregon
Conditions: Caregiver Burden
Leveraging Parents and Peers to Increase Recovery Capital in Emerging Adults
Recruiting
Emerging adults (EAs; aged 18-26) are the highest-risk population for poly-substance use (misuse of more than one drug), compared to all other age groups and are the least-served population for substance use services. The overarching purpose of this pilot study is to assess whether an innovative services package, Launch, can reasonably work (is feasible) and whether providers and participants like it (acceptability). Launch works with both EAs and a supportive parent (or parental figure) and del... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/26/2024
Locations: Chestnut Health Systems, Eugene, Oregon
Conditions: Polysubstance Drug Use (Indiscriminate Drug Use)
MammaPrint, BluePrint, and Full-genome Data Linked With Clinical Data to Evaluate New Gene EXpression Profiles
Recruiting
The FLEX Registry will be implemented to operate as a large-scale, population based, prospective registry. All patients with stage I to III breast cancer who receive MammaPrint® and BluePrint testing on a primary breast tumor are eligible for entry into the FLEX Registry, which is intended to enable additional study arms at low incremental effort and cost. FLEX Registry will utilize an adaptive design, where additional targeted substudies and arms can be added after the initial study is opened.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/26/2024
Locations: Willamette Valley Cancer Institute and Research Center, Eugene, Oregon
Conditions: Breast Cancer
A Masked, Placebo-controlled Study to Assess Iptacopan in Age-related Macular Degeneration
Recruiting
The purpose of this study is to assess the effect of Iptacopan to prevent conversion of early or intermediate age-related macular degeneration (AMD) eyes to new incomplete retinal pigment epithelium and outer retinal atrophy (iRORA) or late AMD.
Gender:
ALL
Ages:
50 years and above
Trial Updated:
06/24/2024
Locations: Retina Northwest PC ., Portland, Oregon
Conditions: Age-Related Macular Degeneration
Phase 3 Study of Toripalimab Alone or in Combination With Tifcemalimab as Consolidation Therapy in Patients With Limited-stage Small Cell Lung Cancer (LS-SCLC)
Recruiting
The Study is a Phase 3, randomized, three-arm, double-blind, placebo-controlled, multi-regional clinical research study to evaluate the safety and efficacy use of toripalimab alone or in combination with tifcemalimab as consolidation therapy in patients with limited-stage small cell lung cancer without disease progression following chemoradiotherapy.
Tifcemalimab is a monoclonal antibody against B and T lymphocyte attenuator (BTLA). Toripalimab is a monoclonal antibody against programmed death... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/19/2024
Locations: Oncology Associates Of Oregon, P.C., Eugene, Oregon
Conditions: Limited-stage Small Cell Lung Cancer (LS-SCLC)
Reducing Intraoperative ESKAPE Transmission Through Use of a Personal Hand Hygiene System
Recruiting
The investigators hypothesize that the use of a personal hand hygiene system (SafeHavenTM) by anesthesia providers in the adult operating room, combined with a novel infectious pathogen tracking system (OR PathTrac) will decrease participant exposure to pathologic bacteria in the adult operating room.
Gender:
ALL
Ages:
Between 18 years and 99 years
Trial Updated:
06/18/2024
Locations: Oregon Health and Science University, Portland, Oregon
Conditions: Surgical Wound Infection, Cross Infection
Phase Ib Trial of Multivalent Autophagosome Vaccine With or Without GITR Agonist, With Anti-PD-1 Immunotherapy in HNSCC
Recruiting
This is a phase Ib study with a safety lead-in (n = 6 per arm) evaluating combinatorial DPV-001 + sequenced PD-1 blockade, with or without GITR agonist, in recurrent or metastatic HNSCC.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/18/2024
Locations: Portland Providence Medical Center, Portland, Oregon
Conditions: Cancer of the Head and Neck
A Study of TSR-022 in Participants With Advanced Solid Tumors (AMBER)
Recruiting
This is a first-in-human study evaluating the anti-T cell immunoglobulin and mucin containing protein-3 (TIM-3) antibody TSR-022. The study will be conducted in 2 parts with Part 1 consisting of dose escalation and Part 2 dose expansion. Part 1 will determine the recommended Phase 2 dose (RP2D) of TSR-022 and Part 2 will evaluate the antitumor activity of TSR-022 in combination with TSR-042 or docetaxel and as monotherapy.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/18/2024
Locations: GSK Investigational Site, Eugene, Oregon
Conditions: Neoplasms
EXHIT ENTRE Implementation Trial of High Intensity Versus Low Intensity Strategy
Recruiting
This study is a multi-site, cluster randomized, two group implementation trial comparing a low- versus high-intensity implementation strategy for supporting hospital-based opioid use disorder treatment (HBOT) in community hospital settings where medication for opioid use disorder (MOUD) treatment has not been implemented.
Gender:
ALL
Ages:
All
Trial Updated:
06/14/2024
Locations: Oregon Health & Science University, Portland, Oregon
Conditions: Substance Use Disorders, Opioid Use Disorder, Severe, Opioid Use Disorder, Moderate
Study of Effect of Azeliragon in Patients Refractory to Prior Treatment of Metastatic Pancreatic Cancer
Recruiting
This is an open label study to determine the safety and preliminary evidence of a therapeutic effect of azeliragon in patients refractory to prior treatment of metastatic pancreatic cancer.
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
06/13/2024
Locations: Williamette Valley Cancer Institute and Research Center, Eugene, Oregon
Conditions: Metastatic Pancreatic Cancer